Efficacy and Safety of Choline Alphoscerate for Amnestic Mild Cognitive Impairment
Study Overview
This study investigated the effectiveness and safety of choline alphoscerate (αGPC) in individuals with mild cognitive impairment. Participants were randomly assigned to receive either αGPC or a placebo for 12 weeks.
Key Findings
After 12 weeks, those who received αGPC showed a significant improvement in cognitive function compared to the placebo group. The αGPC group had a decrease of 2.34 points on the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog).
Safety and Conclusion
No serious adverse events were reported, and participants did not discontinue the intervention due to side effects. The study suggests that αGPC is a safe and effective intervention for individuals with mild cognitive impairment.
Practical Solutions and Value
Clinical trials play a crucial role in developing safe treatments. Our AI-driven platform, DocSym, integrates clinical standards and research to support clinicians. Streamlining operations with mobile apps can improve patient care and expand services digitally, leading to enhanced workflows and better patient outcomes.
Discover how we can assist in optimizing your clinic’s operations at aidevmd.com.
